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The contribution of cell-extrinsic factors in Acute Myeloid Leukemia (AML) generation and
persistence has gained interest. Bitter taste receptors (TAS2Rs) are G protein-coupled
receptors known for their primary role as a central warning signal to induce aversion
toward noxious or harmful substances. Nevertheless, the increasing amount of
evidence about their extra-oral localization has suggested a wider function in sensing
microenvironment, also in cancer settings. In this study, we found that AML cells express
functional TAS2Rs. We also highlighted a significant association between the modulation
of some TAS2Rs and the poor-prognosis AML groups, i.e., TP53- and TET2-mutated,
supporting a potential role of TAS2Rs in AML cell biology. Gene expression profile analysis
showed that TAS2R activation with the prototypical agonist, denatonium benzoate,
significantly modulated a number of genes involved in relevant AML cellular processes.
Functional assay substantiated molecular data and indicated that denatonium reduced
AML cell proliferation by inducing cell cycle arrest in G0/G1 phase or induced apoptosis
via caspase cascade activation. Moreover, denatonium exposure impaired AML cell
motility and migratory capacity, and inhibited cellular respiration by decreasing glucose
uptake and oxidative phosphorylation. In conclusion, our results in AML cells expand the
observation of cancer TAS2R expression to the setting of hematological neoplasms and
shed light on a role of TAS2Rs in the extrinsic regulation of leukemia cell functions.
Keywords: acutemyeloid leukemia, bitter taste receptors, denatonium benzoate, bonemarrowmicroenvironment,
bitter compounds
Salvestrini et al. Bitter Taste Receptors in Leukemia
INTRODUCTION
Acute Myeloid Leukemia (AML) is a clonal disease developing
from a rare population of leukemic stem cells. Alongside
the identification of disease-specific alleles harbored by AML
clones, the contribution that cell-extrinsic factors have in
AML generation and persistence by influencing AML cell
genomic landscape and therapy-resistance is gaining increasing
interest (1, 2). In the cross-talk between AML cells and their
microenvironment, several membrane receptors crucially sense
and respond to external changes by triggering those intracellular
signals, which in turn activate specific pathways. Among these
receptors, the largest group belongs to the family of G protein-
coupled receptors (GPCRs).
In humans, bitter taste receptors (TAS2Rs) comprise 25
distinct members of the GPCR family (3). Initially described in
the oral cavity, TAS2Rs are well-known tomediate the perception
of bitter taste and are associated with a self-defense system
against the ingestion of dangerous and toxic substances (4).
Intriguingly, recent studies have shown that TAS2Rs are also
expressed in many extra-oral tissues, such as the respiratory
and endocrine system, the gastrointestinal tract, reproductive
tissue and the brain (5–9). Although these extra-oral functions
are still poorly understood, some evidence suggests that TAS2Rs
may represent a receptor system, used by different cell types to
sense external stimuli (10–13). Indeed, in the gastrointestinal
tract TAS2Rs function by sensing luminal content and hormones
(10). Throughout the respiratory epithelium, TAS2Rs are found
in solitary chemosensory cells and in the airway smooth muscle,
where they respectively mediate protective airway reflex and
bronchodilation (11, 12). In the upper respiratory tract, TAS2Rs
are directly activated by bacterial products and contribute to
immune responses by favoring the production of antimicrobial
substances from mucosal cells (13).
Cancer cells, including leukemia cells, are known to
adapt and turn ancestral and phylogenetically conserved
functional pathways into malignant settings (14). Notably,
TAS2R expression has recently been reported in diverse tumor
types, including neuroblastoma (15), pancreatic (16), prostate
(17), ovarian (17), and breast cancer (18). However, no clear
evidence of their function has been provided, although a potential
role in cancer biology has been recently suggested. A stimulation
of T2R38 in pancreatic cancer upregulates the multi drug
resistance protein ABCB1, a major player in the induction of
chemoresistance (19). Singh et al. demonstrated a differential
expression of TAS2Rs in non-cancerous breast epithelial vs.
breast cancer cells, with some TAS2Rs downregulated in breast
cancer cells (18). Moreover, it has been reported that TAS2R4
Abbreviations: TAS2R, bitter taste receptor; GPCR, G protein-coupled receptor;
DEN, denatonium benzoate; BM, bone marrow; qRT-PCR, quantitative Real-
time PCR; fura-2/AM, fura-2/acetoxymethyl ester; CDC25A, cell division cycle
25 homolog A; CDK2, cyclin-dependent kinase 2; PLK1, polo-like kinase 1;
pH2AX, histone 2AX; GSEA, Gene set enrichment analysis; GEP, Gene Expression
profiling; ROS, reactive oxygen species; CFU, colony-forming unit; OXPHOS,
oxidative phosphorylation; OCR, Oxygen Consumption Rate; PER, proton
efflux rate; FCCP, Carbonyl cyanide-p-trifluoromethoxyphenylhydrazone; ECAR,
Extracellular Acidification Rate.
and TAS2R14 are involved in the regulation of proliferation
and migration of highly metastatic breast cancer cells (20). In
neuroblastoma cells, TAS2R8 and TAS2R10 play an important
role in inhibiting the self-renewal potential and the invasion
ability of cancer cells (15). On the other hand, several bitter
compounds and several agonist for TAS2Rs have has been found
to exhibit anticancer or chemotherapy enhancing activities,
whereby the exact mechanisms are often unknown (21–27).
In this study, for the first time, we characterized TAS2R
expression in AML cells and we investigated the effects of a
stimulation with denatonium benzoate (DEN), a widely used
bitter taste agonist which has been demonstrate to activate
TAS2Rs on various cell types (10, 28–31). Our data provide
evidence that bitter compounds can modulate leukemia cell
genetic profile and functions.
METHODS
Cell Isolation and Culture
Primary leukemic cells (AML cells) from 47 patients at
diagnosis (blasts > 80%) were obtained from bone marrow
(BM) or peripheral blood (PB), upon signed informed consent
(Table S1). Mononuclear cells were separated by density gradient
centrifugation (Lympholyte, Cedarlane, Burlington, Canada).
Human leukemia cell lines OCI-AML3, THP-1 were purchased
from DSMZ (Braunschweig, Germany) and used between
passages 10 and 25. Knockout (CRISPR-Cas9 targeting TAS2R4,
TAS2R10, TAS2R8, TAS2R13, or TAS2R30 genes) THP-1 cells
were purchased from Synthego Inc (Redwood City, CA, USA).
All cells culture were maintained at the concentration of 5 x
105/ml in RPMI 1640 medium supplemented with 10% FBS
(Thermo Fisher Scientific,Waltham,MA,USA) at 37◦C, 5%CO2,
w or w/o increasing doses of denatonium benzoate (dissolved
in RPMI 1640 medium), quinine and chloroquine (dissolved in
ethanol and water, respectively) (Sigma Aldrich, St. Louis, MO,
USA). This research was approved by the Ethics Committee of
Policlinico S. Orsola-Malpighi, University Hospital of Bologna
(approval code: 94/2016/O/Tess).
Gene Expression Profiling (GEP)
TAS2R expression was analyzed in 61 AML, 49 from a published
dataset (32) and 12 new cases. As validation set, we used
also 183 AML samples downloaded from The Cancer Genome
Atlas (TCGA) (https://gdc.cancer.gov/about-data/publications/
laml_2012) (33). GEP after DEN treatment was performed
in 5 newly diagnosed AML samples and THP-1 and OCI-
AML3 cell lines. Three independent replicates of each condition
were hybridized to Human Clariom S Arrays (Thermo Fisher
Scientific) according to the manufacturer’s recommendations.
Data quality control, normalization (signal space transformation
robust multiple-array average), and supervised analysis were
carried out by Expression Console and Transcriptome Analysis
Console software, respectively (Thermo Fisher Scientific). For
AML cells, data were normalized on vehicle-treated cells before
comparison. Genes with a 1.5-fold difference and p ≤ 0.05 were
considered for enrichment analyses. Downstream analyses were
performed as reported in (32, 34), and with Thomson Reuter’s
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MetaCore software suite (Clarivate Analytics, Philadelphia, PA,
USA). Gene expression data of denatonium-treated cells will
be publicly available on the GEO database under the accession
number GSE128414.
qRT-PCR
MNCs were isolated from BM aspirates of AML samples at
diagnosis. Fresh isolated cells were lysed in RLTplus buffer
(Qiagen, Hilden) and stored at −80◦C for the following steps.
Stored RLT lysed were defrosted all at once and processed for
RNA extraction as described above.
AML cell lines, cultured as described before, were seeded at 5
x 105/ml and the day after were lysed in RLTplus buffer, stored at
−80◦C and processed as described for AML primary samples.
Total RNA was isolated using a Rneasy Micro kit (Qiagen)
according to the manufacturer’s instructions and quantified
by Nanodrop ND-1000 spectrophotometer (Thermo Fisher
Scientific). RNA samples were treated with DNase (Thermo
Fisher Scientific) and reverse transcribed (35). The qRT-PCR
reactions were performed using a 96-well Optical Reaction Plate
and an ABI-PRISM 7900 Sequence Detection System (Thermo
Fisher Scientific) (35). The threshold cycle (Ct) values for
target genes and endogenous reference gene (Table S2) were
determined automatically. Relative quantification was calculated
using the 1Ct comparative method (34). cDNA from Universal
RNA (Agilent genomics, Santa Clara, CA, USA) was used as
reference sample. All reactions were performed in duplicate.
Cytosolic Ca2+ Concentration
Measurements
Cytosolic free Ca2+ concentrations were measured in a
thermostat-controlled (37◦C) and magnetically-stirred Cary
Eclipse Fluorescence Spectrophotometer (Agilent Technologies)
with the fluorescent indicator fura-2/AM (36). Briefly, 2 × 106
cells were loaded with 2µM fura-2/AM for 20m in the presence
of 1mM CaCl2 and 250µM sulfinpyrazone in the following
saline solution: 125mM NaCl, 5mM KCl, 1mM MgSO4, 1mM
NaH2PO4, 20mM HEPES, 5.5mM glucose, 5mM NaHCO3, pH
7.4. Subsequently, cells were rinsed, and resuspended at a final
concentration of 1 x 106/ml in the same buffer supplemented,
whenever required, with 1mM CaCl2, or 500µM EDTA or
10µM BAPTA-AM. In the latter case, to ensure for BAPTA-
AM entry inside the intracellular compartments and complete
chelation of stores’ calcium cells were also pre-incubated with
BAPTA-AM at 37◦C for 30min before proceeding to fluorimetric
measurements. Cells were stimulated with 10mMDEN or 75µM
quinine, following signal stabilization. Excitation ratio and
emission wavelengths were 340/380 and 505 nm, respectively.
Western Blot Analysis
AML cells were lysed at 4◦C for 30min in Cell Lysis
Buffer (Cell Signaling Technology, Danvers, MA, USA), with
1mM Phenylmethanesulfonyl fluoride (Sigma Aldrich). Protein
extracts (30 µg) were separated using a 10–12% Mini-
PROTEAN R© TGX Stain-Free Precast Gels (Bio-Rad, Hercules,
CA, USA), transferred on membranes and incubated with the
indicated antibodies (Table S3). Reactive proteins were revealed
using ECL Select (GE Healthcare, Chicago, IL, USA). Precision
Plus Protein Kaleidoscope (Bio-Rad) was used as a protein
molecular weight standard.
Viability and Proliferation Assay
5 x 105 cells/100 µl culture medium were seeded into a 96-well
microplate and treated as indicated. After culture, CellTiter 96
AQueous One Solution reagent (Promega, Madison, WI, USA)
was added to each well and the microplate was incubated for
4 h in standard conditions, according to protocol’s instruction.
The optical density value was measured by an ELISA plate
reader (Multiskan Ex, Thermo Fisher Scientific) at a wavelength
of 492 nm. Each condition was analyzed in triplicate. CellTiter
Glo (Promega) was used in some experiments. According
to protocol’s instruction, 100 µl CellTiter Glo reagent was
added into each well, the plates were briefly mixed by an
orbital shaker and incubated for 10min at room temperature.
Luminescence was recorded by the Sparke multiplate reader
(Tecan, Männedorf, Switzerland). Each variant group was
performed in triplicate wells.
Progenitor Cell Assays
1 x 105 AML cells were resuspended in 100 µl 10% FBS/Iscove’s
modified Dulbecco’s medium and cultured in 1ml of semisolid
methylcellulose medium supplemented with cytokines
(StemMACS HSC-CFU lite with Epo, Miltenyi, Teterow,
Germany) according to the manufacturer’s specifications.
Leukemic colony forming units (CFU- L) were scored after
10–12 days of incubation in standard conditions.
Apoptosis
Apoptosis was measured with Annexin-V-FLUOS Staining Kit
(Roche, Basel, Switzerland) according to the manufacturer’s
instructions. Briefly, 1 x 106 cells were resuspended in 100 µl
of Incubation Buffer, stained with 2 µl of FITC-conjugated
Annexin-V and 2 µl of propidium iodide (PI) for 10min at room
temperature and analyzed by flow cytometry (AccuriTM C6, BD,
Franklin Lakes, NJ, USA) and FCS Express 4 Software, De Novo
Software, Glendale, CA, USA).
Active Caspase-3 Expression
Cells were treated with a Fixation/Permeabilization kit (BD) for
intracellular staining and incubated with anti-active Caspase-3
PE antibody (#550821) (BD), according to standard protocol and
analyzed by flow cytometry as described.
For immunofluorescence staining, cells were fixed in
4% paraformaldehyde, permeabilized with PBS/0.25% and
stained with anti-Caspase-3 antibody (#700182) (Invitrogen,
Carlsbad, CA, USA) and secondary antibody (#F0205) (Agilent
Technologies). Stained cells were examined under fluorescence
Axiovert microscope (Zeiss, Germany).
Mitochondrial Membrane Potential (19m)
Measurement
19m was investigated using the BDTM MitoScreen Kit (BD)
according to the manufacturer’s instructions. Briefly, 1 x 106 cells
were harvested, washed twice with PBS and incubated with JC-1
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solution for 15min at 37◦C. JC-1 monomers or aggregates were
analyzed by flow cytometry.
Seahorse XF Cell Mito Stress Test
Cell Mito Stress Test (XF Cell Mito Stress Test Kit, Agilent
Technologies) was performed following the standard protocol
(37). Briefly, THP1 and OCI-AML3 were seeded at the
concentration of 5 x 105/ml in a 24-well plate and treated with
increasing doses of DEN. After 24 h incubation, growth medium
from each well was replaced by pre-warmed assay medium (pH:
7.4) and counted. Cell were seeded at 50.000/well for THP1 and
150.000/well for OCI-AML3 in Seahorse 96-well plates coated
with CellTak (BD Biosciences, San Jose, CA, USA) to facilitate
attachment. OCR and Extracellular Acidification Rate (ECAR)
were detected after injection of oligomycin (1µM), Carbonyl
cyanide-p-trifluoromethoxyphenylhydrazone (FCCP) (0.5µM),
and rotenone & antimycin (Rot/AA) combination (0.5µM). In
selected experiments, glycolytic proton efflux rate (glycoPER)
was detected using the Seahorse XF Glycolytic Rate Assay
(Agilent Technologies) for measuring glycolysis by injecting
Rot/AA (0.5µM) and 2-deoxy-D-glucose (2-DG) (50mM). The
assays were both performed by using the XFe96 analyzer (Agilent
Technologies) and the data were analyzed by the Wave software
(version 2.2.0, Seahorse Bioscience) after normalization.
Migration Assay
Cell migration was tested using transwell assays (diameter
6.5mm, pore size 8µm Corning Costar, Corning, NY, USA)
(38). Briefly, 100 µl RPMI 10% FBS containing 1 x 105 cells
was added to the upper chamber, while 600 µl medium w or
w/o 150 ng/ml CXCL-12 (Meridian Life Science) was added to
the bottom chamber. DEN was added to the upper or to the
bottom chamber, in order to evaluate its priming or chemotactic
activity, respectively. After overnight incubation at 37◦C in 5%
humidified CO2 atmosphere, inserts (upper chambers) were
removed and cells transmigrated into lower chamber were
recovered and counted. The number of migrating cells was
counted with an inverted microscope (Nikon, Tokyo, Japan)
using a 5 times magnification.
In some experiments, cells were pre-incubated for 4 h with
DEN, which was washed out before migration assay.
In silico Gene Expression Analysis
For in silico analysis, all calculations were performed using R
version 3.6.1. CEL files raw data were normalized using Robust
Multi-Array Average (RMA) and log2 transformed. In the TCGA
datasets downloaded, the Affymetrix U133 Plus 2 was used
to perform RNA-expression profiling, containing the following
TAS2R transcripts probes: TAS2R1, TAS2R3, TAS2R4, TAS2R5,
TAS2R7, TAS2R8, TAS2R9, TAS2R10, TAS2R13, TAS2R14,
TAS2R16, TAS2R38, TAS2R39, TAS2R40, TAS2R41, TAS2R43,
TAS2R45, TAS2R50. The differential expression levels of TAS2Rs
were assessed in (1) 183 AML samples and (2) in association
with clinical data, by the limma package (Bioconductor) (39).
For all statistical analysis, we considered p-value < 0.05 and
Benjamini–Hochberg adjusted p-values< 0.05.
Statistical Analysis
Statistical analysis was performed using the unpaired two-tailed
Student’s t-test for comparisons between two groups or two-
way ANOVA followed by post-hocDunnett’s test for comparisons
between three or more groups (GraphPad Prism 6.03, GraphPad
Software, San Diego, CA, USA). Results are expressed as means
± SD, unless otherwise indicated. P < 0.05 was considered
statistically significant.
RESULTS
AML Cells Express Fully Functional TAS2Rs
Based on the evidence of an extra-oral role of TAS2Rs, we
investigated their expression and potential involvement in AML
cell regulation. We analyzed gene expression microarray datasets
of 61 samples of AML patients at diagnosis. First of all, we
investigated the distribution of TAS2Rs transcript level among
AML samples, highlighting a strong heterogeneity in the TAS2R
expression genes (Figure 1A). Based on the log2 expression
level, TAS2R transcripts were expressed in AML samples
and in particular TAS2R43, TAS2R13, TAS2R14, TAS2R30/47,
TAS2R31/44 showed a higher level of TAS2RmRNAs than others.
To validate the above results we downloaded gene expression
profiling CEL files from the TCGA AML cohort consisting of
183 samples. The correspondence of gene expression level of
TAS2Rs was very similar to our observations, as we have seen for
TAS2R43, TAS2R10, TAS2R14 expression (Figure S1A). TAS2R
mRNA expression levels were also assessed by qRT-PCR in an
independent cohort of 13 AML samples and OCI-AML3 and
THP-1 cell lines.
Despite the trend of the TAS2Rs expression level were similar
in the 61 AML and in the 183 in silico AML samples, the qRT-
PCR confirmed the trend for only 6 of the 21 TAS2Rs tested
but showing the positivity for almost all TAS2Rs (Figure 1B).
This discrepancy is probably due to different size of highly
heterogeneous analyzed samples.
As GPCRs, TAS2Rs work together with gustducins, a class
of taste receptor-specific G proteins, stimulating, through PLC-
β2 activation, a signaling cascade leading to the calcium release
from intracellular stores (40). Thus, we found that AML cells
and cell lines expressed the β-gustducin and the PLC-β2, at
mRNA and protein level, indicating that the necessary factors
for canonical bitter taste signaling pathway are also present
(Figures 1C,D). We noted that PLC-β2 mRNA was expressed
at lower amounts in AML cell lines as compared to the AML
primary cells (Figure 1C), while PLC-β2 protein expression levels
seemed to be similar. This suggested the existence of some
mechanism/s of PLC-β2 mRNA upregulation in AML primary
samples and/or selective post-transcriptional events modulating
PLC-β2 expression levels.
We next stimulated OCI-AML3 and THP-1 cell lines with
three bitter compounds denatonium, quinine, and chloroquine
and we determined the activity of TAS2Rs by analyzing calcium
mobilization after stimulation. A rapid increase in calcium
activity was seen in response to denatonium and quinine using
the fura-2/acetoxymethyl ester (fura-2/AM) assay (Figure 1E
and Figure S1B), while the response to chloroquine was almost
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FIGURE 1 | TAS2R expression in AML. (A) Box plots illustrate relative TAS2R mRNA expression obtained by GEP in primary AML samples (n = 61). (B) Box plot
illustrate TAS2R mRNA expression analysis by qRT-PCR in primary AML samples (n = 13) and AML cell lines, THP-1 and OCI-AML3. Error bars refer to THP-1 and
OCI-AML3 sample triplicates. Relative TAS2R expression levels were calculated using GAPDH as endogenous control and commercial cDNA pool as the reference
sample was taken as 1 (2−11Ct method). Melt curve analysis confirmed the presence of a single PCR product and Ct values of expressed targets ranged between 25
and 30. (C) qRT-PCR analysis of TAS2R downstream targets in primary AML samples and AML cell lines. Relative target expression levels were calculated as
described in (A). Error bars in AML columns refer to the 13 analyzed samples. THP-1 and OCI-AML3 samples were analyzed in triplicates. (D)Western blot analysis of
the downstream targets in two AML cell lines and five AML samples (Pt). Actin was shown as the loading control. (E) Ca2+ release in a representative AML sample
and AML cell lines loaded with the Ca2+ indicator fura-2/AM and treated with 10mM denatonium (indicated as D) or 75µM quinine (indicated as Q) in presence of
EDTA (indicated as E) or BAPTA-AM (indicated as B) buffer.
null (not shown). To ascertain whether the measured increase
of intracellular calcium was due to store-operated calcium
release, as expected from TAS2R activation, or extracellular
calcium influx we performed the same experiments in the
presence of BAPTA-AM or EDTA. Figure 1E shows that,
while both chelating agents reduce basal intracellular calcium
levels, only BAPTA-AM, which is known to obliterate calcium
present in intracellular stores, leads to a loss of calcium
release into the cytosol following stimulation with denatonium
and quinine. However, we observed a slight increase of
calcium release also in presence of BAPTA-AM in AML
primary samples after stimulation with denatonium, suggesting
an involvement of other TAS2R-independent pathways as
well (41).
Taken together, these results demonstrate that AML cells
express functional TAS2Rs.
TAS2R Expression Levels Correlate in silico
With Some AML Clinical Parameters
To corroborate the significance of TAS2R expression in AML, we
investigated a potential relationship between TAS2R transcript
levels and clinical parameters in AML patients. To this aim,
we performed an association analysis on 183 AML samples
from a public database for which clinical data were available.
Considering the recurrently mutated genes TP53, FLT3, NPM1,
DNMT3A, TET2, RUNX1, IDH1, IDH2 in AML, we found
a statistically significant association between TP53 mutated
samples and a lower expression of TAS2R9 (p-value = 0.008)
and TAS2R10 (p-value = 0.03) and between TET2 mutated
samples and a lower expression of TAS2R9 (p-value = 0.04)
(Figures 2A,B). By analyzing the association between TAS2R
expression level and the cytogenetic andmolecular risk, we found
that a low expression of TAS2R9 was significantly associated with
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FIGURE 2 | Association between TAS2R transcript levels and clinical parameters in AML patients. (A,B) Boxplots of different expression level of TAS2R10 and
TAS2R9 in TP53 and TET2 mutated and wild-type samples; (C–E) Boxplots of the indicated TAS2Rs based on Cytogenetic molecular and FAB clinical features.
Statistical analysis were performed by Student’s t-test and Benjamini–Hochberg adjusted p-values correction.
both cytogenetics (p-value = 0.005) and molecular poor risk (p-
value = 0.02) (Figures 2C,D) and a low expression of TAS2R14
(p-value = 0.02) was associated with a poor molecular risk
(Figure 2D). Considering FAB classification, we also observed a
significant association between a reduction in mRNA expression
level of TAS2R10 (adjust BH p-value = 0.007), TAS2R5 (adjust
BH p-value = 0.03), and TAS2R14 (adjust BH p-value = 0.045)
and a more differentiated status of AML blast (Figure 2E). Any
significant association was found between TAS2R expression
levels and other parameters as age, sex, and or blast percentage in
the BM. These data indicate that the expression of some TAS2Rs
may be not randomly clustered with some relevant cell-intrinsic
alterations of AML cells, providing the rationale for better
investigating the functional relevance of TAS2Rs stimulation in
AML cells.
TAS2R Stimulation by DEN Alters the
Expression of Genes Involved in AML Cell
Function
To test the TAS2R function, we decided to use DEN as a
model compound since, compared to quinine, DEN targets fewer
TAS2Rs that could be downregulated in AML patients. DEN
exerts their effects by activating 9 out 25 TAS2Rs (42), 5 of which
(T2R4, T2R8, T2R10, T2R13, and T2R30/47) are expressed also
at protein level both in AML samples and in AML cell lines
(Figure 3A). We tested the DEN effective/not toxic (43) dose by
exposing primary AML cells andOCI-AML3 and THP-1 cell lines
to increasing doses of DEN and analyzed cell viability. After 48 h
of exposure, DEN reduced both cell line and AML cell viability
in a dose-dependent manner (Figure 3B). However, due to the
high grade of redundancy in the expression of DEN-sensitive
TAS2Rs, we could not identify a unique candidate in charge of
the observed effect by using knockdown cells (Figure 3C).
To identify the cellular processes regulated by TAS2Rs
in AML cells, we performed GEP after in vitro activation
of the TAS2R pathway by DEN. Overall, DEN induced the
upregulation of 190, 260 and 1109 genes and the downregulation
of 325, 570 and 929 genes in primary AML, OCI-AML3
and TPH-1 cells, respectively (Figure 4A). Although several
genes were uniquely altered in the analyzed cells, interestingly,
a core transcriptional program of 45 upregulated and 87
downregulated genes was shared between OCI-AML3 and THP-
1 cells (Figure 4A and Table S4). Among them, 8 genes were
significantly downregulated also in primary cells (Figure 4A
and Table S4). Downregulated transcripts in AML cells were
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FIGURE 3 | Denatonium affects leukemia cell viability. (A) Western blot analysis of the denatonium-sensitive T2Rs in two AML cell lines and five AML samples (Pt).
Actin was shown as the loading control. (B) Cell viability detected by CellTiter 96 Aqueous One Solution assay in AML samples (n = 7) and AML cell lines (n = 3 for
each cell line) treated for 48 h with increasing doses of DEN. (C) Cell viability detected by CellTiter-Glo assay in THP-1 wild type and in T2R4, T2R8, T2R10, T2R13,
and T2R30 knockout THP-1 (n = 3 for each cell line).
significantly enriched for genes involved in the cell cycle and
DNA damage, cytoskeletal function, cell adhesion and migration,
and pyrimidinemetabolism (Figure 4B andTable S5). Moreover,
DEN treatment altered the expression of genes involved
in apoptosis, carbohydrate, energy, amino acid, and lipid
metabolism in AML cells (Figure 4B). Among apoptosis-related
genes, TP53INP1, RNF130, CFLAR, TNFSF10 were upregulated
and AIFM2 was downregulated in both OCI-AML3 and THP-
1 (Table S4). The two cell lines also shared the deregulation
of genes involved in cytoskeletal function, cell adhesion
and migration (upregulated: PIK3R5; downregulated: TUBA8,
FSCN1, HMMR, RHOF, EMD) and cell cycle/DNA damage
(upregulated: FRY, LIG4, AKAP9; downregulated: ORC1, SPDL1,
NCAPG2, RAD54B, NCAPG, KIF22, PBK, BTG3, CDC25A,
CDC45, PLK1, CDC20, CDCA3, CCNF, CCND1, CENPV,
FANCG). Differentially expressed transcripts in the tested cell
lines were enriched for genes involved in cell cycle, DNA
damage and glycolysis (Tables S6, S7). According to pathway
analysis, cytoskeletal function, cell adhesion and migration, fatty
acid biosynthesis, and glycolysis were significantly enriched in
OCI-AML3 (Table S6), while THP-1 cells showed a preferential
enrichment for transcriptional alterations targeting metabolism-
related genes, including bioenergetics pathways (glycolysis
and mitochondrial respiration), biosynthetic processes (purine,
nucleotides, amino acids), and lipid metabolism (fatty acid,
cholesterol) (Table S7). Gene set enrichment analysis (GSEA)
corroborated pathway analysis (Figure S2).
Overall, our data suggest that the TAS2R pathway induction
by DEN deregulates relevant cellular processes in AML cells,
including cell cycle, survival, migration, and metabolism.
DEN Inhibits AML Cell Proliferation and
Clonogenic Efficiency
Consistently with the molecular studies, exposure to non-toxic
doses of DEN exerted an antiproliferative effect on AML cells
in vitro. OCI-AML3 and THP-1 proliferation was significantly
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FIGURE 4 | Transcriptomic alterations induced by DEN in AML. (A) The number of upregulated and downregulated genes after 24 h of denatonium exposure in
primary AML cells (0.5mM), OCI-AML3 (0.1mM), and THP-1 (0.5mM) cell lines. (B) Heatmap of differentially expressed genes involved in apoptosis, cell cycle and
DNA damage, cytoskeleton, cell adhesion and migration, and metabolism, following exposure to denatonium in three primary AML sample. Columns represent ratios
between DEN- and vehicle-treated cells for each case. Color changes are quantified by the scale bar. Genes are ranked according to their fold change.
reduced after 48 h of DEN treatment, (Figure 5A). Cell cycle
analysis showed that the inhibitory effect of DEN was mainly
due to a G0/G1-phase arrest and a concomitant S-phase decrease
(Figure 5B).
To substantiate these data, Western blot analysis was used to
validate the expression of cell cycle proteins, which GEP analysis
indicated as deregulated at the mRNA level. The expression of
cyclin D1 and cyclin A2, which normally increased during G1
(44) and S phase progression (45) respectively, was significantly
reduced following DEN-treatment in both cell lines (Figure 5C).
In parallel, the phosphatase cell division cycle 25 homolog A
(CDC25A), able to activate G1/S cyclin-dependent kinase 2
(CDK2) (46), decreased in DEN-treated cells. Instead, CDK2 was
downregulated to a lesser extent, according to an inactivation
mechanism based on cyclin level oscillation during the cell cycle
(47). Consistently with a cell cycle arrest, the expression of a
typical mitotic protein, i.e., polo-like kinase 1 (PLK1), whose
activation relies on Cyclin A2-Cdk activity levels (48), was
significantly inhibited in DEN-treated cells (Figure 5D). GEP
analysis also highlighted that differentially expressed transcripts
were enriched for genes involved in DNA repair (e.g., RAD54B,
XRCC3, and FANCG showed reduced expression in both cell
lines after treatment). Accordingly, protein expression analysis
showed an increase in the phosphorylated form of the histone
2AX (pH2AX) following DEN treatment in AML cell lines
(Figure 5C), indicating an increase in DNA damage, probably
due to impaired DNA repair activity.
To evaluate the TAS2R stimulation effect on the growth
properties of leukemic progenitor cells, colony growth was
determined by CFU assay using increasing doses of DEN. Non-
toxic doses of DEN significantly inhibited CFU-L formation
already at the lowest dose and up to 50% inhibition at the highest
doses (Figure 5E).
Overall, these results support GEP data, suggesting that AML
cells respond to TAS2R signaling pathway activation at low doses
of DEN by accumulatingDNAdamage and reducing proliferative
and clonogenic potential.
Exposure to High Doses of DEN Induces
AML Cell Apoptosis
Since GEP data showed modulation of genes involved in
apoptosis and exposure to high doses of DEN induced a
significant reduction of AML cell viability, we evaluated the
potential cytotoxic effect of TAS2R stimulation. Thus, we treated
AML cells (n= 10), OCI-AML3 and THP-1 cells with increasing
doses up to 2mM DEN and analyzed the cells after Annexin-
V/PI staining. As shown in Figures 6A,B, necrosis induction was
not observed, as demonstrated by the absence of a PI+/Annexin-
V− cell population. Conversely, there was a 3-fold increase of
the percentage of AML apoptotic cells at the high doses of
agonist compared to control. The same results were obtained
in OCI-AML-3 and THP-1 cells (Figures S3A,B). To better
characterize apoptosis after DEN treatment, we evaluated caspase
cascade activation by analyzing the expression of caspase 3 active
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FIGURE 5 | DEN stimulation inhibits AML cell proliferation and clonogenic ability. (A) Cell proliferation determined by CellTiter 96 Aqueous One Solution assay and
normalized to time 0 in THP-1 (n = 3) and OCI-AML3 (n = 3) cultured for 48 h with increasing doses of DEN. (B) Histograms display cell cycle phase distribution in
(Continued)
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FIGURE 5 | AML cell lines after 48 h of DEN exposure (n = 5). (C)Western blot analysis of the indicated proteins in two AML cell lines treated with the indicated doses
of DEN for 24 h. Actin was shown as the loading control. (D) Percentage of PLK1+ cells analyzed by flow cytometry in AML cell lines treated with the indicated doses
of DEN for 24 h (n = 4). (E) Histograms indicate the fold-change of the CFU-L obtained from primary AML cells cultured in semisolid medium in the presence of
cytokines and increasing concentration of DEN (n = 7). The mean number of colonies in control was 22 ± 12 and taken as 1. Data are expressed as mean ± SEM in
(A–D) and as mean ± SD in (E). Statistical analysis was performed by using ANOVA followed by Dunnett’s multiple comparison test with untreated group as control.
*p < 0.05; **p < 0.01; ***p < 0.001.
form. Flow cytometry (Figures 6C,D) and immunofluorescence
(Figure 6E) revealed an increased expression of active-caspase 3
in AML cells after DEN exposure. Similar results were obtained
in AML cell lines (Figure S3C). To confirm mitochondrial
involvement in apoptosis after DEN treatment, we stained
AML cells with JC-1 dye, which accumulates as aggregates or
monomers in healthy or damaged mitochondria, respectively.
As shown in Figures 6F,G, 48 h of DEN exposure reduced
1Ψm in treated compared to untreated AML cells, as
demonstrated by the 2-fold increase of JC-1 monomers and
the concomitant significant decrease of JC-1 aggregates. Similar
results were obtained in AML cell lines (Figures S3D,F).
The induction of apoptosis is probably independent of
reactive oxygen species (ROS) activation since DEN was
unable to induce ROS production in the tested AML cells
(Data not shown).
Taken together, our results indicate that AML cells undergo
apoptosis after TAS2R stimulation by high DEN dose through
caspase and mitochondria pathway activation.
DEN Alters AML Cell Mitochondrial
Metabolism
GSEA indicated a significant enrichment for a gene signature
of glycolysis and gluconeogenesis/citric acid cycle/oxidative
phosphorylation (OXPHOS) in untreated compared to DEN-
treated leukemia cells (Figure 7A and Figure S4A), suggesting
an alteration in cellular bioenergetics after DEN exposure. To
confirm GSEA and GEP data, we measured cellular bioenergetics
following mitochondrial metabolic stress. As shown by Oxygen
Consumption Rate (OCR), DEN treatment decreased both
basal and maximal mitochondrial respiration (Figure 7B and
Figure S4B). Specifically, mitochondrial basal respiration was
significantly disrupted, as evidenced by the basal respiration drop
of more than 50% (Figure 7C and Figure S4C). These results are
also consistent with a 2-fold decrease in ATP-linked respiration
in DEN-treated cells, in both THP-1 and OCI-AML3 (Figure 7D
and Figure S4D). Respiratory spare capacity represents the
reserve capacity of a cell to generate ATP via OXPHOS following
an increased energy demand. Thismitochondrial reserve capacity
was reduced by more than 50% in DEN-treated compared to
untreated cells (Figure 7E and Figure S4E). These data suggest
that DEN treatment decreased mitochondrial (mt)OXPHOS
and makes AML cells more prone to oxidative and metabolic
stress due to decreased substrate availability or mitochondrial
dysfunction. Concomitantly, to further characterize the relative
utilization of glycolysis and OXPHOS after DEN treatment, we
performed the Glycolytic Rate Assay, measuring basal glycolytic
rates and compensatory glycolysis following mitochondrial
inhibition. Despite no difference in terms of basal glycolysis
(Figures S5A,C), high doses of DEN (0.5mM) increased the
percentage of proton efflux rate (PER) from glycolysis in THP-
1 (Figure S5B). Consistent with the dropped level in the basal
respiration detected by Mito Stress assay, these data suggest that
glycolysis, rather than mitochondrial-derived CO2, is the main
contributor to extracellular acidification and PER. However, at
the same concentration, DEN is able to markedly impair the
compensatory glycolysis achieved by the cells after blockage
of mitochondrial ATP production (Figure 7F). In OCI-AML3,
DEN showed a lower impact in terms of glycolytic activity
(glycoPER) (Figures S4F, S5D). Importantly, as indicated by
mitoOCR/glycoPER basal ratio (Figure 7G and Figure S4G),
DEN decreased of 70% the rate of acidification in both
OCI-AML3 and THP-1 due to mitochondrial metabolism,
indicating that DEN shifts the bioenergetics profile of the
cells from OXPHOS toward aerobic glycolysis, likely impaired
under stress.
We hypothesized that the observed reduction of both
mtOXPHOS and glycolysis could also be due to reduced
glucose uptake after DEN exposure. As shown in Figure 7H and
Figure S4H, we observed a significant decrease in glucose uptake
in DEN-treated compared to untreated cells.
Overall, the results suggest that DEN-treated cells are unable
to maintain basic cell function and to use both mitochondrial
respiration and glycolysis, showing a defective metabolic and
quiescent phenotype.
DEN Exposure Inhibits AML Cell Motility
GEP data suggested that AML cell motility was affected
by DEN treatment. Thus, we tested the DEN effect on
AML cell migratory capacity by using the transwell system.
When increasing doses of DEN were added to the transwell
upper chamber, the direct exposure to DEN reduced by
about 50% the spontaneous migration of primary AML cells,
even at the lower dose (Figure 8A). Similar results were
obtained in AML cell lines (Figure S6A). Moreover, the
inhibition persisted even if the stimulus was removed from the
medium. Indeed, pre-treatment with DEN of both AML cells
(Figure 8B) and cell lines (Figure S6B) reduced of 30% their
spontaneous migration. Furthermore, the motility inhibition
was even remarkable in the presence of a DEN gradient,
obtained through the addition of DEN to the transwell lower
chamber (Figure 8C and Figure S6C). The CXCL-12-CXCR4
axis, the key mediator in hematopoietic stem cell migration,
is exploited by AML cells and regulates their trafficking
in the BM microenvironment. Therefore, we wondered if
DEN exposure affected the CXCL-12-CXCR4 axis. In presence
of DEN, AML cells reduce by about 30% their migration
toward the chemoattractant agent CXCL-12 (Figure 8D and
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FIGURE 6 | DEN induces AML cell apoptosis. (A) AML cells (n = 10) were treated for 48 h with increasing doses of DEN. Annexin V/PI staining was used to detect
apoptosis. (B) Representative FACS analysis of apoptosis after treatment with 1mM DEN. (C) FACS analysis of active caspase-3 expression in AML cells after
treatment with 1mM DEN for 48 h (n = 6). (D) Representative overlay histograms of Active caspase-3 expression. (E) Immunofluorescence analysis of activated
caspase-3 (green) after 48 h of treatment with 1mM DEN. Nuclei were counterstained with DAPI (blue). 40X magnification, scale bar 20µm. (F) FACS analysis of
mitochondrial membrane potential of AML cells after 48 h of exposure to 1mM DEN. The histogram shows the percentage of JC-1 aggregates (cells emitting red
fluorescence in the FL-2 channel) and JC-1 monomers (cells emitting green JC-1 detected in the FL-1 channel) (n = 6). (G) Representative dot plots of JC-1 staining.
Data are expressed as mean ± SD. Statistical analysis was performed by using ANOVA followed by Dunnett’s multiple comparison test with untreated group as
control and by Student’s t-test. *p < 0.05; **p < 0.01.
Figures S6D,E). Moreover, DEN exposure induced a 0.7 fold-
change of the CXCR4 surface expression (Figure 8E and
Figure S6F).
Next, we investigated whether DEN altered AML cell
interaction with extracellular matrix components, which play
a key regulatory role in cell motility and trafficking. Using
fibronectin-coated culture wells, we found that DEN treatment
did not induce a significant modulation of AML cell adhesion
capacity and did not affect the expression of CD49e, CD49d, and
CD29 integrins (data not shown).
These results suggest that exposure to DEN attenuates
leukemia cell migration likely through the inhibition of the
CXCR4-CXCL-12 axis rather than AML cell adhesion to the
extracellular matrix in vitro.
DISCUSSION
In the present work, for the first time, we demonstrated that
TAS2Rs are involved in the regulation of leukemia cell functions.
TAS2Rs are known for their primary role as a central warning
signal to induce aversion toward noxious or harmful substances.
Nevertheless, the increasing amount of evidence about their
extraoral localization has suggested a wider function in sensing
microenvironment, also in cancer settings.
Our data, obtained from AML cell lines and primary AML
cells extend our knowledge about the expression of TAS2Rs to
the field of the hematological malignancies.
We showed that AML cells express TAS2Rs, coupled with
the canonical signaling components such as the β-subunit of
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FIGURE 7 | DEN alters mitochondrial bioenergetics. (A) Downregulation of gene signatures of glycolysis, citrate cycle and OXPHOS defined by GSEA in THP1 cells
after 24 h of exposure to DEN. (B) Oxygen consumption rate (OCR) profile plot obtained by the Seahorse Cell Mito Stress Test in the THP-1 cell (n = 4) after 24 h of
exposure to increasing doses of DEN. (C) Basal respiration. (D) ATP-linked respiration. (E) Spare capacity. (F,G) Quantitative data of compensatory glycolysis and
ratios of mitochondrial OCR to glycoPER calculated using Seahorse XF Glycolytic Rate assay (n = 3). (H) Measurement of glucose uptake in THP-1 cells after 24 h
exposure to increasing doses of DEN (n = 5). Untreated cells (193,001 ± 44,454 RLU) were used as a reference and set as 1. Data are expressed as mean ± SEM.
Statistical analysis was performed by using ANOVA followed by Dunnett’s multiple comparison test with untreated group as control. *p < 0.05; **p < 0.01; ***p <
0.001. NES, normalized enrichment score; FDR, false discovery rate.
gustducin and PLC-β2. In bitter taste signal transduction, β/γ
subunits of G-proteins are known to initiate the dominant
branch of the pathway, via PLC-β2 activation and calcium
release (40, 49, 50). To substantiate TAS2R functionality in AML
cells, we stimulated AML cells with DEN and quinine, two
putative TAS2R ligands, commonly used for TAS2R activation
(11, 41, 51–53) and we found that both significantly mobilized
intracellular calcium. TAS2R activation is known to increase
intracellular calcium due to store-operated calcium release (54).
Accordingly, when calcium present in intracellular stores had
been obliterated, we found a loss of calcium release following
stimulation with denatonium and quinine. Although we cannot
rule out a concomitant TAS2R-independent effect of bitter
compounds in AML cells, i.e., via direct interaction with ion
channels (41), these data indicate that, at least in part, TAS2R
activation is involved in the effect of DEN and quinine on calcium
mobilization, corroborating an on-target activity.
Supporting a potential functional role of TAS2Rs in AML
cells, the expression of TAS2Rs has been significantly correlated
in a large cohort of AML patients with some relevant biologic
features, commonly used for diagnosis and risk stratification.
In particular, we observed a significant modulation of some
TAS2Rs in poor-prognosis AML groups, TP53-mut and TET2-
mut patients, in line with the observed TAS2R level decrease
in breast cancer cells with a more aggressive phenotype (18).
Although far from being conclusive, our in silico correlative
results support the idea of a potential TAS2R role in AML
cell biology.
To identify the cellular processes regulated by TAS2Rs in
AML cells, we performed a GEP analysis after exposure to
the TAS2R agonist, DEN. A consistent number of genes were
differentially expressed in AML cells following DEN treatment.
Interestingly, pathway enrichment analysis indicates that diverse
and relevant cellular processes, amongwhich cell cycle, apoptosis,
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FIGURE 8 | DEN stimulation inhibits AML cell migration. Results of AML cell migration in transwell assays were shown as fold-change of the percentage of migration
in comparison with the untreated condition set as 1. (A) Spontaneous migration of AML cells in presence of increasing doses of DEN in the upper chamber of
(Continued)
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FIGURE 8 | transwell (n = 6). The percentage of migrating cells in control samples was 29.5 ± 6.3 SD. (B) Spontaneous migration of AML cells after a pre-treatment
of 4 h with increasing doses of DEN (n = 8). The percentage of migrating cells in control samples was 34.3 ± 11.3 SD. (C) Migration of AML cells toward a gradient of
DEN in the lower chamber of transwell (n = 5). The percentage of migrating cells in control samples was 32.0 ± 9.7 SD. (D) The histogram shows the effect of the
presence of 0.1mM DEN in the upper or the lower chamber on the CXCL-12 induced chemotaxis (150 ng/ml). The percentage of migrating cells in control samples
was 34.1 ± 12.8 SD (n = 5). (E) CXCR4 expression analyzed by flow cytometer after overnight treatment with DEN (n = 6). The percentage of CXCR4+ cells in
untreated samples was 23.6 ± 13.1 SD. Data are expressed as mean ± SD. Statistical analysis was performed by using ANOVA followed by Dunnett’s multiple
comparison test with untreated group as control and by Student’s t-test. *p < 0.05; **p < 0.01; ***p < 0.001.
cell adhesion, migration, and metabolic activity are targeted
by TAS2R pathway induction. The activation of these specific
pathways was confirmed in functional in vitro experiments. All
these pathways, only seemingly unrelated, concur to corroborate
an “anti-proliferative” effect due to DEN treatment.
In healthy human airway smooth muscle cells and ovarian,
prostate and breast cancer cell lines TAS2R-stimulation by
DEN provides an anti-proliferative signal (17, 20, 55, 56).
Accordingly, we found that stimulation with DEN inhibits AML
cell proliferation. We also observed a DEN-dependent inhibitory
effect on AML cell clonogenic capacity, a peculiar feature of
leukemic cells, which is known to impact on prognosis (57, 58).
However, the high grade of redundancy in the expression of
TAS2Rs did not help to identify a unique candidate accounting
for the TAS2R-mediated phenotype, also by using knockdown
cells. Because it is known that an imbalance between cell
proliferation and apoptosis is a hallmark in tumor cells (59,
60), we investigated the possibility that DEN could influence
apoptotic mechanisms in AML cells. DEN exposure induces
AML cell apoptosis through caspase and mitochondria pathway
activation. Interestingly, we found that this effect is not observed
in normal TAS2R-expressing CD34+ cells which are almost
entirely unaffected (manuscript in preparation). These results
suggest that DEN induces anti-tumor biological responses, and
they are in agreement with recent reports suggesting that TAS2R
activation, together with an anti-proliferative effect, induce
apoptosis in breast, prostate, and ovarian cancer cells (17, 20).
In this light, downregulation of some TAS2R, as observed in
subgroups of patients, in particular in TP53- and TET2-mutated,
might be a strategy adopted by AML cells to evade possible
growth-suppressive effects, as demonstrated in breast cancer cells
(18). However, due to the high AML heterogeneity, additional
transcriptomic analysis on larger sample size and specific TAS2R-
inactivation experiments are necessary, before drawing any
meaningful conclusion.
We also found that DEN is able to alter mitochondria
metabolism in AML cells. Changes in mitochondrial metabolism
indicate adaptation to stress conditions and increased nutrient
demand and could influence the cell-cycle progression and
vice versa (61). Our data indicate that DEN-treated cells have
significantly limited mitochondrial activity with a shift of the
bioenergetic profile from OXPHOS to aerobic glycolysis, which,
however, is likely impaired in stress conditions as also indicated
by GEP data. Taken together, these data suggest that DEN
concomitantly inhibits the mitochondrial OXPHOS and induce
a “quiescent state” by arresting the cell-cycle progression.
The effects of DEN treatment on the migration of AML cells
were also examined. Interestingly, DEN exposure mitigated both
the spontaneous migration and the migration in the presence
of a chemotactic gradient of CXCL-12. The observed inhibition
of migration is possibly correlated with cell cycle arrest and
Cyclin D1 and Cyclin A2 decrease. Indeed, beyond their role in
cell cycle progression, Cyclin D1 and Cyclin A2/CDK2 complex
are also involved in cellular structure organization and motility
regulation (62, 63). Consistently, upon exposure to DEN, non-
proliferating AML cells have reduced cell motility and migration,
whichmay contribute to the AML cell anchorage in the protective
BM niche and eventually generate resistance to therapy. A similar
TAS2R-dependent phenotype has been already characterized in
breast cancer cells (20). Our results are also in agreement with the
previously reported role of TAS2R8 and TAS2R10 in abrogating
migration of neuroblastoma cells (15).
Several natural bitter compounds, flavonoids and iso-
flavonoids have displayed anti-cancer effects against various
cancer types (25, 64–68) similar to DEN. Many of these
compounds are recognized as TAS2R agonists (69, 70) but it is
still unclear if the anticancer effects evoked by these bioactive
compounds aremediated by TAS2R engagement or other indirect
and unknown mechanisms. Despite the mechanism and the
specific TAS2R involved in each process remains to be elucidated,
our data suggests that “bitter” molecules present endogenously
in the BM microenvironment, such as amino acids (71, 72),
or extrinsic factors, such as drugs (42, 73), might interact with
TAS2Rs and affect leukemia cell functions. Since, previous data
(74) and our unpublished observations indicated that TAS2R
were expressed also in healthy hematopoietic cells, we could
speculate that TAS2R may represent a novel receptor-based
pathway by which blood cells “taste” their microenvironment and
respond to it accordingly.
In conclusion, our results in AML cells expand the observation
of cancer TAS2R expression to the setting of hematological
neoplasms and shed light on a role of TAS2Rs in the extrinsic
regulation of leukemia cell functions.
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